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Abstract  23 
Gestational diabetes mellitus is defined by new-onset glucose intolerance during 24 
pregnancy. About 2-5% of all pregnant women develop gestational diabetes during 25 
their pregnancies and the prevalence has increased considerably during the last 26 
decade. This metabolic condition is manifested when pancreatic β-cells lose their 27 
ability to compensate for increased insulin resistance during pregnancy, however, 28 
the pathogenesis of the disease remains largely unknown. Gestational diabetes is 29 
strongly associated with adverse pregnancy outcome as well as with long-term 30 
adverse effects on the offspring which likely occurs due to epigenetic modifications 31 
of the fetal genome. In the current review we address gestational diabetes and the 32 
short and long term complications for both mothers and offspring focusing on the 33 
importance of fetal programming in conferring risk of developing diseases in 34 
adulthood. 35 
  36 
Keywords: gestational diabetes mellitus, fetal programming, epigenetics 37 
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 1. Gestational Diabetes Mellitus- overview 39 
Gestational diabetes mellitus (GDM) is defined by glucose intolerance of various 40 
degrees with first recognition during pregnancy [1-3]. In the USA, GDM affects up to 41 
10% of all pregnancies and immediately after pregnancy, 5 to 10% of women with 42 
GDM are found to have type 2 diabetes mellitus (T2DM) [4]. Although GDM usually 43 
resolves within 6 weeks of delivery, approximately 50% of women diagnosed with 44 
this metabolic condition are expected to develop T2DM over 10-30 years [4,5]. 45 
Women with GDM experience an increased risk of developing other pregnancy 46 
complications, such as preeclampsia, and their offspring are at higher risk of 47 
developing short-term adverse outcomes such as macrosomia, neonatal 48 
hypoglycemia and neonatal cardiac dysfunction, and long-term complications, such 49 
as obesity, impaired glucose tolerance (IGT), and diabetes in adolescence or early 50 
adulthood [2,4,6].  51 
During pregnancy, glucose metabolism changes to meet the nutritional demands of 52 
the mother and fetus [7]. It has been demonstrated that fasting glucose 53 
concentrations of women with normal glucose tolerance decreases as gestation 54 
progresses [8]. Although the mechanism is complex and still not well understood 55 
potential contributing factors have emerged, including: increased plasma volume in 56 
early gestation, increased glucose consumption due to increased feto-placental 57 
glucose intake in late gestation, and/or inadequate hepatic glucose production 58 
comparative to circulating glucose concentrations [3,7,8]. Nonetheless, despite the 59 
decrease in fasting glucose, hepatic glucose production is increased in normal 60 
pregnancy [7]. Insulin resistance occurs to some degree in all pregnancies [2,9]. In 61 
fact, by late pregnancy, women’s insulin sensitivity declines to one third in 62 
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comparison to their non-pregnant state. This increased insulin resistance facilitates 63 
continuous glucose transfer to the fetus [10]. In order to maintain proper glucose 64 
control, β-cell mass as well as the amount of insulin secreted from β-cells increases 65 
during pregnancy [7]. Pregnant women who develop GDM, however, are unable to 66 
increase insulin production to compensate for their increased resistance to insulin 67 
[3,7,9,11].  68 
GDM is considered to result from interaction between genetic and environmental risk 69 
factors [12]. Studies have suggested that pregnancy triggers a series of metabolic 70 
imbalances that lead to a diabetic state in some women who are already genetically 71 
predisposed to develop diabetes [3]. Indeed, a study by Shaat et al, has identified a 72 
variant in the transcription factor-7-like 2 (TCF7L2) gene to be associated with an 73 
increased risk of GDM [13]. Furthermore, women with mutations in maturity onset 74 
diabetes of the young (MODY) genes, with common variants in potassium inwardly-75 
rectifying channel subfamily J, member 11 (KCNJ11), glucokinase (GCK) and 76 
hepatocyte nuclear factor-1alpha (HNF1α) have been demonstrated to be at higher 77 
risk of developing GDM [12]. More recently, a two-stage genome-wide association 78 
analysis in Korean women found genetic variants in the CDK5 Regulatory Subunit 79 
Associated Protein 1-Like (1CDKAL1) gene and near the Melatonin Receptor 1B 80 
(MTNR1B) gene to be strongly associated with GDM. Interestingly, they also provide 81 
evidence that GDM and T2DM share a similar genetic background [14]. 82 
In addition, obesity or overweight, advanced maternal age, glycosuria, personal 83 
history of GDM or a strong first-degree family history of T2DM and gestational 84 
diabetes are important factors and warning signs which increase the risk of GDM 85 
[3,15-17]. 86 
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Numerous reports demonstrate the prevalence of GDM is increasing globally. Over 87 
the past 20 years, GDM has increased by approximately 10-100% [17-23], 88 
particularly in populations immigrating from less- to more-developed areas [24]. 89 
Population ageing, urbanization, obesity, sedentary lifestyles and stressful modern 90 
life are thought to be contributing factors in this emerging public health problem. In 91 
addition to adverse consequences for infants in the newborn period, GDM also 92 
contributes to the increasing incidence of diabetes and obesity in women with GDM 93 
and their offspring later in life [17,25]. Indeed, the Exploring Perinatal Outcomes 94 
among Children (EPOCH) study found that youth exposed to maternal GDM in utero 95 
had significantly higher average BMI over this range (p=0.01) and an accelerated 96 
BMI growth trajectory (p=0.008) compared with unexposed youth (Figure1) [26]. 97 
While all these factors are attributed to the epidemic of GDM, intrauterine exposures 98 
and gestational programming also play a role [25]. Coordinated efforts are required 99 
to provide better perinatal management and postpartum diabetes prevention 100 
strategies in order to alter these trends and to evade the ‘vicious cycle’ in which 101 
diabetes begets more diabetes.  102 
2. GDM and perinatal programming 103 
Fetuses exposure to maternal diabetes have a higher risk of abnormal glucose 104 
homeostasis in later life beyond that attributable to genetic factors [25,27,28]. 105 
Indeed, it is currently widely accepted that an abnormal in utero stimulus or ‘insult’ 106 
has the ability to disrupt the normal pattern of fetal development, permanently 107 
changing its body’s structure, physiology and metabolism, thereby, predisposing to 108 
chronic diseases in later life. This phenomenon is referred to as fetal or gestational 109 
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programming [28-32].  This hypothesis was first introduced by David J. Barker [29] 110 
who proposed “…that poor fetal and early post-natal nutrition imposes mechanisms 111 
of nutritional thrift upon the growing individual”  leading to increased rates of future 112 
cardiovascular disease [33-35], hypertension [36-38], and T2DM [33,39]. Since the 113 
discovery that low birth weight is associated with increased risk of developing T2DM 114 
and the metabolic syndrome [33,39], numerous epidemiologic and experimental 115 
studies have confirmed these associations. In the current review, we will revise 116 
epidemiological studies that support the fetal programming theory and analyze the 117 
link between maternal diabetes and altered glucose homeostasis in the offspring. We 118 
will also discuss the possible cellular and molecular mechanisms behind this 119 
association. 120 
2.1 Epidemiology and clinical observations of fetal programming 121 
Dörner was among the first to provide epidemiological evidence that gestational 122 
diabetes or even slightly impaired glucose tolerance during pregnancy increases the 123 
risk of obesity and diabetes in offspring [40,41]. More direct evidence that adverse 124 
intrauterine environment might predispose to long-term T2DM came from a follow-up 125 
study of men and women from Hertfordshire, UK, in middle and later life whose body 126 
measures at birth had been recorded, showing, for the first time, that those who had 127 
had low birthweights presented increased risk of developing T2DM and impaired 128 
glucose tolerance in adult life [39]. When this theory was first proposed, it was 129 
regarded with much skepticism. The main criticism was that the sample selection 130 
was biased due to losses to follow-up owing to missing data on birth or incomplete 131 
identification. Other issues regarding the associations observed are potential 132 
confounding socioeconomic and environmental factors which could attribute to the 133 
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chronic diseases, per se, such that low birthweight alone might not be dictated as an 134 
independent risk factor. Notwithstanding, several other studies have confirmed this 135 
association [33,42-48], further suggesting that maternal undernutrition is able to 136 
permanently change insulin-glucose metabolism in the fetus, thus programming 137 
insulin resistance and T2DM in the offspring. These observations indicate that there 138 
is a linear inverse correlation between birthweight and T2DM. Nevertheless, in utero 139 
exposure to high glucose concentrations and to maternal diabetes, forces the fetus 140 
to increase its own insulin production, generally leading to excessively growth, a 141 
condition known as large for gestation age or macrosomic fetus [3,49]. Among Pima 142 
Indian Americans, a population with a particularly high prevalence of diabetes and 143 
obesity, it was reported, for the first time, that the prevalence of T2DM was greatest 144 
in those with the lowest and highest birthweights and the risk for subsequent 145 
diabetes among higher birthweight infants (over 4.5 kg) was entirely associated with 146 
maternal diabetes during pregnancy [45]. This demonstrates the importance of 147 
intrauterine exposure to impaired maternal glucose metabolism, even within a 148 
population that may have increased genetic susceptibility to T2DM. Further 149 
epidemiologic [50-52] and experimental [53,54] studies have demonstrated that high 150 
birthweight is associated with increased risk of T2DM in later life to the same extent 151 
as low birthweight. Taken together, these data indicate that, in fact, not a linear-152 
inverse but a U-shaped relationship exists between weight at birth and future risk of 153 
developing T2DM and obesity (“diabesity”), with increased risk at both ends of the 154 
birthweight curve [31,32,45,51,52]. 155 
Given the increasing prevalence of “diabesity” among women of reproductive age in 156 
developed and Westernized developing countries, this may decisively contribute to 157 
the increasing frequency of high birth weight and therefore to greater diabetes 158 
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susceptibility in the offspring. Indeed, various studies have provided further evidence 159 
that offspring of mothers with uncontrolled diabetes, either pre-existing or originating 160 
during pregnancy, are 4-8 times more likely to develop diabetes in later life 161 
compared to those born from non-diabetic mothers. And a female born from a GDM 162 
pregnancy has a higher chance of developing GDM during her pregnancy, thus, 163 
creating a recurring disease cycle [55-57]. A way to counteract this tendency would 164 
be to avoid and/or adequately correct maternal overweight and/or maternal diabetes 165 
during pregnancy [17,25]. In line with this, a recent follow-up study of children of 166 
women un-treated versus treated for mild GDM demonstrated that treatment during 167 
pregnancy is associated with lower fasting glucose in female offspring at ages 5-10 168 
years but not in male offspring. However, none of the children of treated or untreated 169 
mothers had diabetes at 5-10 years, suggesting that treatment of mild maternal 170 
diabetes may not affect childhood obesity or metabolic health [58]. Therefore, the 171 
possibility that fetal programming in the setting of maternal diabetes can have a 172 
beneficial offspring effect that can be modified by treatment remains unknown. 173 
Larger follow-up studies in pregnancy randomized trials are needed to provide 174 
evidence that the diabetes cycle can be interrupted. 175 
2.2 Mechanisms 176 
2.2.1 Pancreatic Development 177 
Accumulated evidence points for a fetal developmental programming of later glucose 178 
metabolism dysfunction, however, the molecular mechanisms by which intrauterine 179 
exposure to hyperglycemia contributes to the development of obesity and diabetes 180 
are still not well understood. It is generally accepted that fetal programming results 181 
from a combination of mechanisms acting at organ, tissue, cellular and molecular 182 
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levels [32]. For example, current knowledge on the development of the pancreas in 183 
humans suggests that it may be particularly sensitive to an altered glucose and 184 
amino acid environment as it achieves complete development during late gestation 185 
and the perinatal period [29,32]. In fact, reduced β-cell mass was demonstrated in rat 186 
fetuses of hyperglycemic dams, with reduced expression of insulin-like growth factor 187 
2 [59]. Moreover, as recently reviewed by Portha et al., the offspring of mild diabetic 188 
mothers, induced experimentally by streptozotocin (STZ) that selectively destroys β-189 
cells, presented normal weight and enhanced percentage of pancreatic endocrine 190 
tissue, leading to higher β-cell mass. On the other hand, fetuses from severe diabetic 191 
dams were small at birth and had decreased pancreatic weight and degranulated β-192 
cells, leading to low pancreatic insulin content and low plasma insulin. The long-term 193 
consequences evaluated in the progeny of these models revealed impaired glucose 194 
tolerance in the offspring of mild STZ diabetic rats due to lower insulin secretion in 195 
response to glucose, while insulin resistance was reported in the offspring of the 196 
severe STZ diabetic mothers [60]. Additionally, Hales et al. suggest that poor early 197 
development of islets of Langerhans and β-cells is a major factor in the etiology of 198 
T2DM [29]. Such alteration in the pancreas development, though, only compromise 199 
function later in life, when increasing physiologic requirements and over-solicitation 200 
of insufficient organ mass start to induce organ damage [32].  201 
2.2.2 Placental role in GDM 202 
The placenta fulfills several critical roles during pregnancy: not only is the regulator 203 
of materno-fetal transport of nutrients and gases but also a source of hormonal 204 
signals that influence maternal and fetal metabolism [30]. The placenta is in a 205 
continuous state of development throughout pregnancy with regulated periods of 206 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
branching angiogenesis, non-branching angiogenesis, trophoblast differentiation and 207 
syncytium formation [30]. Thus, when exposed to intrauterine adverse conditions, the 208 
placenta either changes the pattern of developmental (hormonal) signals to the fetus 209 
or the amount of nutrients/oxygen transported to the fetus [30,61] to such an extent 210 
that fetal development is altered, leading to long-term consequences throughout life 211 
[30,61,62]. The timing of the disruption of this development pattern is critical to 212 
determine the consequence on placental function and hence programming of the 213 
fetus [30,32]. 214 
Placentas from GDM pregnancies present characteristic histological features such 215 
as villous immaturity, villous fibrinoid necrosis, chorangiosis, and increased 216 
angiogenesis [63]. Generally, if impaired glucose metabolism is diagnosed in the 217 
early pregnancy, mainly structural dysfunctions are observed, whereas if detected in 218 
late gestation, GDM will affect placental function to a greater extent inflammation and 219 
oxidative stress that can lead to the chronic fetal hypoxia Diabetic insults at the 220 
beginning of gestation instigates placenta adaptive responses to the diabetic 221 
environment, such as buffering excess maternal glucose or increased vascular 222 
resistance, which may lead to limited fetal growth. If the duration or extent of the 223 
diabetic insult, including maternal hyperglycemia, hyperinsulinemia, or dyslipidemia, 224 
exceeds the placental capacity to mount adequate responses, then excessive fetal 225 
growth may ensue [64]. Furthermore gene expression studies suggest that GDM is 226 
characterized by changes in trophoblast cells that include up-regulation of genes 227 
involved in a multitude of cellular functions including, immune response, organ 228 
development, regulation of cell death and also genes regulating inflammatory 229 
responses and endothelial reorganization reflecting a state of chronic systemic 230 
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inflammation of placentas of women with GDM that could ultimately lead to the 231 
chronic fetal hypoxia [65,66]. 232 
Fetal glucose production is minimal, therefore, the fetus depends almost completely 233 
on the maternal glucose supply. Since glucose is able to cross the placenta, fetuses 234 
from hyperglycemic mothers are inevitably predestined to grow in an environment of 235 
greater than normal glucose concentration [32]. The transplacental glucose flux 236 
follows as maternal-to-fetal concentration gradient and is handled by the transporter 237 
isoforms of the glucose transporters (GLUTs) family of proteins. It has been shown, 238 
however, that materno-fetal glucose transport is flow-limited and not regulated by 239 
transporter availability [61,62]. Indeed, recent observations in placenta perfusion 240 
studies found no difference in transplacental glucose transport between placentas 241 
from GDM and normal pregnancies at a fixed maternal-to-fetal glucose gradient 242 
[67,68]. Hence, these data indicate that the placenta is not involved in enhanced 243 
maternal-to-fetal glucose transfer in GDM and that the increased glucose flux across 244 
the placenta observed in GDM depends entirely on maternal-to-fetal concentration 245 
gradient [61,62]. Regarding the long-term effects of in utero exposure to a 246 
continuous range of high glucose concentrations throughout pregnancy, the 247 
Pedersen hypothesis is generally accepted. According to this proposition, maternal 248 
hyperglycemia increases glucose transfer to the fetus, thereby leading to fetal 249 
hyperglycemia, which in turn stimulates islet cell proliferation and insulin production 250 
[69]. This phenomenon generally leads to macrosomia, which has been associated 251 
with increased risk of later obesity and diabetes [70,71]. Moreover the 252 
overstimulation of fetal β-cells usually leads to hypertrophy of the tissue. This event, 253 
coupled to a higher fetal utilization of glucose could explain several abnormal 254 
structure and changes found in the newborn [69]. Indeed, the hyperglycemia and 255 
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adverse pregnancy outcome (HAPO) study suggested a positive linear correlation 256 
between maternal glucose and a range of adverse outcomes for the baby, including 257 
high birthweight and hypoglycemia [72]. 258 
2.2.3 Development plasticity and epigenetics 259 
Many lines of evidence indicate that early life events play a powerful role in 260 
influencing later susceptibility to certain chronic diseases, such as T2DM, coronary 261 
heart disease, and hypertension. Despite all the explanations mentioned above, the 262 
molecular mechanisms through which the intrauterine exposure to hyperglycemia 263 
would translate into the development of diabetes are yet to be unraveled. An 264 
increased understanding on the developmental plasticity- defined as the ability of an 265 
organism to develop in various ways, depending on the particular environment [73], 266 
provides a conceptual basis to understand the association between fetal 267 
programming and adult disease. Developmental plasticity requires stable modulation 268 
of gene expression, and this appears to be mediated, at least in part, by epigenetic 269 
processes. In fact, accumulated evidence suggests that both the genome and the 270 
epigenome can interactively influence the phenotype determining sensitivity to later 271 
environmental factors and the subsequent risk of disease [74]. Recently published 272 
studies provide supporting evidence that epigenetic modifications may establish a 273 
better understanding on the mechanism whereby hyperglycemia influences T2DM in 274 
the offspring [75,76].  275 
Although the genetic code of an organism is homogeneous, each individual cell type 276 
possesses its own gene-expression pattern that defines each cell’s biological fate. 277 
Stable alterations of this gene-expression profile are named ‘epigenetic’ 278 
modifications because they are heritable changes in gene expression without 279 
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alteration of the DNA sequence [77]. Most of these heritable changes are 280 
established during differentiation and are stably maintained through cell division, 281 
enabling cells to have distinct identities while containing the same genetic 282 
information [78]. DNA methylation and histone modifications are the best-known 283 
epigenetic mechanisms [79]. DNA methylation is the most extensively studied 284 
epigenetic signature [78] and it involves the covalent modification of cytosine 285 
residues that precede guanines- CpG dinucleotides, with the “p” referring to the 286 
phosphodiester bond between the cytosine and guanine nucleotides [80]. The CpG 287 
dinucleotides are not evenly distributed across the human genome but are instead 288 
clustered in CpG-rich regions known as CpG islands, spanning the 5′ regulatory end 289 
of many genes [78]. On the other hand, histone proteins which comprise the 290 
nucleosome core, contain a globular C-terminal domain and an unstructured N-291 
terminal tail. The N-terminal tails of core histones can normally be altered post-292 
translationally by a variety of modifications, including methylation, acetylation, 293 
ubiquitylation, SUMOylation and phosphorylation [78]. Histone modifications can 294 
function by changing the accessibility of chromatin or by recruiting and obstructing 295 
non-histone effector proteins, leading to either activation or repression depending 296 
upon which residues are modified and the type of modifications present. For 297 
example, lysine acetylation usually correlates with transcriptional activation, whereas 298 
lysine methylation leads to transcriptional activation or repression depending upon 299 
which residue is modified and the degree of methylation [78]. Epigenetic marks are 300 
mitotically stable but can also be subject to reprogramming in response to 301 
environmental stimuli such as changes in diet, physical activity, in utero environment, 302 
and pharmacological treatment [80]. Therefore, epigenetic signatures serve as a 303 
connection between life environment and phenotypes. 304 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
Although data in humans are still limited, accumulating evidence has provided 305 
insights into the involvement of epigenetic mechanisms in the developmental 306 
programming of obesity and T2DM later in life. A study of individuals who were 307 
prenatally exposed to famine during the Dutch Hunger Winter in 1944-1945 308 
revealed, six decades later, lower DNA methylation of the imprinted insulin-like 309 
growth factor-2 (IGF2) gene, which has a role in growth and development, compared 310 
with their unexposed, same-sex siblings [81]. The same authors went on to further 311 
characterize DNA methylation, from whole blood, at 15 genomic loci harboring genes 312 
implicated in growth, development, and metabolic disease [82]. Again, adults who 313 
had been exposed to prenatal famine, exhibited altered methylation levels in the 314 
promoters of six of the chosen genes: DNA methylation of the interleukin 10 (IL10), 315 
leptin (LEP), ATP-binding cassette, sub-family A, member 1 (ABCA1), guanine 316 
nucleotide binding protein, alpha stimulating-antisense RNA (GNAS-AS), and 317 
maternally expressed 3 (MEG3) gene promoters was higher among individuals 318 
prenatally exposed to Dutch famine in comparison with their unexposed same-sex 319 
siblings [82]. Another report demonstrated an association between macrosomic 320 
babies and an increased placental methylation of the glucocorticoid receptor gene, 321 
which is a well-known candidate gene for obesity [83]. This study not only associates 322 
perinatal growth as a measure of the intrauterine environment with epigenetic 323 
alterations of the glucocorticoid receptor gene but also suggests a critical role for 324 
DNA methylation in determining placental function [83].  325 
Recent studies have explored the role of epigenetics in offspring exposed to GDM. 326 
For instance, two candidate-gene studies of placental tissue, maternal circulating 327 
blood cells and cord blood cells from women with and without GDM, revealed that 328 
maternal glucose levels were associated with placental LEP [84], and adiponectin 329 
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[85] methylation providing a potential link between maternal hyperglycemia, fetal 330 
programming and long-term risk of obesity. Another study compared the methylation 331 
pattern in peripheral blood leukocytes from non-diabetic adolescent Pima Indians 332 
who were either offspring of diabetic mothers or offspring of non-diabetic mothers. 333 
Using a methylated DNA immunoprecipitation (Me-DIP-chip) assay differential 334 
methylated regions were assayed and subsequent in silico pathway analysis 335 
identified maturity onset diabetes of the young (MODY), T2D and Notch signaling as 336 
the top 3 enriched pathways with differentially methylated genes. These pathways 337 
include genes which are important in pancreatic development, β-cell response to 338 
glucose as well as insulin secretion [86], highlighting the potential impact of 339 
intrauterine hyperglycemia on methylation of genes implicated in β-cell function, 340 
thereby predisposing the offspring to increased risk of diabetes. Recently, a study 341 
using the 2-step epigenetic Mendelian randomization approach found that maternal 342 
glycemia is part of the causal pathways leading to higher leptin levels in cord blood 343 
with DNA methylation as a mediator of this association [87]. This study supports that 344 
maternal glycemia leads to epigenetic adaptations in the LEP region of the offspring, 345 
potentially contributing to long-term programming of excessive adiposity later in life. 346 
Although these studies provide exciting insights into possible epigenetic signatures 347 
that may contribute to long-term programming of obesity and metabolic disorders, 348 
one has to bear in mind that small samplings were included and these studies also 349 
lack of independent replication, hence the methylation changes detected often do not 350 
reach biological levels of significance. 351 
It is relevant to mention that children whose mothers had diabetes during pregnancy 352 
are at increased risk of becoming obese and developing diabetes at young ages. 353 
Furthermore, many of these female offspring already have diabetes or abnormal 354 
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glucose tolerance by the time they reach their reproduction age, prolonging the cycle 355 
of diabetes [88]. There is some evidence that epigenetic and phenotypic traits 356 
induced by early life environment can be passed from one generation to the next 357 
[89], however, there is no evidence that it is the case for GDM. 358 
3. Clinical aspects  359 
As stated before, GDM is associated with short and long term complications, both for 360 
the mother and for the child. Fetal and newborn short-term complications include 361 
respiratory distress syndrome [90], prematurity, breech presentation [91], 362 
hypoglycemia, hyperbilirubinemia, macrosomia and death [92].  Macrosomia, defined 363 
as fetal weight over 4000g, is the most common fetal complication, and is associated 364 
with several perinatal adverse outcomes, such as acute fetal distress, birth trauma 365 
and emergency cesarean section [92]. In addition to these immediate risks, there are 366 
significant long-term risks of later life obesity, glucose intolerance, hypertension and 367 
cardiovascular disease in children of diabetic mothers [49]. 368 
The HAPO study has firmly established that maternal hyperglycemia, even at levels 369 
that do not meet the definition of GDM, is closely linked to macrosomia and 370 
excessive fetal growth [49] and also establishes a directly proportional relationship 371 
between maternal glycaemia and primary cesarean-section and neonatal 372 
hypoglycemia [72]. Also, treating milder hyperglycemia with lifestyle interventions 373 
and/or drug therapy, reduces mean blood sugar levels and improves outcomes. Two 374 
randomized trials using insulin have shown that glucose lowering strategies reduce 375 
birth weight, the proportion of large for gestational age infants, cesarean-section and 376 
perinatal morbidity [93,94]. Moreover, several publications about the use of oral 377 
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hypoglycemic agents, such as glibenclamide and metformin for the treatment of 378 
GDM [95-97], have shown the same results in terms of glycemic control or 379 
pregnancy outcomes compared with insulin. Even thought, treatment of GDM, 380 
whether with diet or with pharmacologic intervention, has shown to improve maternal 381 
and infant outcome in the short term, no long-term studies evaluating the impact of 382 
maternal glycemic control on the child’s future metabolic complications are available. 383 
The current diagnosis of GDM is made during the late second trimester, which 384 
means the pathological state has already been established influencing the 385 
programming of the fetus. 386 
Different testing strategies have been evaluated for diagnosis of GDM to improve 387 
maternal and infant health. A recent study by Farrar et al. has evaluated and 388 
compared different testing strategies for the diagnosis of GDM. For instance, when 389 
comparing 75-gram oral glucose tolerance test (OGTT) versus 100-gram OGTT, 390 
women given the 75-gram OGTT had a higher relative risk of being diagnosed with 391 
GDM, however there was insuficcient evidence to allow assessment of which 392 
strategy is best for GDM diagnosis [98]. Furtermore, this trial did not evaluate when 393 
is the best timing during pregnancy to test women with GDM. The formal diagnostic 394 
criteria for GDM involve an OGTT at 24- 28 weeks gestation. Different countries and 395 
organizations have different standards and cut-off points to define normal glucose 396 
tolerance and to define GDM but the International Association of Diabetes and 397 
Pregnancy Study Group (IADPSG) has recently determined new and lower 398 
thresholds, in the light of data indicating that glucose lowering strategies improve 399 
pregnancy outcomes even in women with mild glucose intolerance [93]. Although a 400 
glucose challenge test at 24-28 weeks is diagnostically robust, it has the 401 
disadvantage of being time consuming and difficult to extend to the whole 402 
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population. Another big disadvantage is the time during pregnancy when the test is 403 
performed, since it does not facilitate early management of GDM, exposing the fetus 404 
to a hyperglycemic environment for the whole of the first and part of the second 405 
trimester. This is important because there is evidence that fetuses exposed during 406 
early pregnancy to hyperglycemia had accelerated growth patterns from the first 407 
trimester onwards [99], highlighting the need for development of diagnostic models 408 
for GDM early in pregnancy to better stratify and predict risk of long term GDM-409 
related complications and offer targeted intervention.  410 
4. Conclusion and implications for prevention 411 
Maternal diabetes is strongly linked to adverse pregnancy outcome, with clear 412 
evidence that exposure to maternal diabetes in utero has long term adverse effects 413 
on the offspring. This likely occurs due to epigenetic modifications of the fetal 414 
genome, and as such could be averted by therapy applied during pregnancy. 415 
Although treatment of extreme maternal hyperglycaemia improves pregnancy 416 
outcomes in the short term, the long term effects of treatment, and the threshold of 417 
maternal glycemia at which therapy is optimally applied is unknown. Further 418 
research is required to address both of these important issues. Possible topics of 419 
research that could help improve clinical GDM treatment and prevention of fetal 420 
programming are summarised in Table 1. 421 
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Highlights 
• Gestational diabetes prevalence is increasing globally. 
• Fetal programming predisposes for future diseases in diabetic mothers and 
offspring. 
• Need to stablish perinatal management and postpartum diabetes prevention 
strategies. 
• Long term complications could be predicted by early-pregnancy diagnostic 
models for GDM. 
 
